elizabeth loder, md, professor of neurology, harvard medical school; chief, division of headache, brigham & women's hospital.
.
.
. at any time but parts of our site will not function correctly without them.
.
eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.
.
.